Literature DB >> 15231387

Mechanism of the interferon alpha response against hepatitis C virus replicons.

Ju-Tao Guo1, Ji A Sohn, Qing Zhu, Christoph Seeger.   

Abstract

Interferon alpha (IFN-alpha) inhibits hepatitis C virus (HCV) replication in vivo and in cell cultures by one or several mechanisms that are not yet understood. We sought to identify the viral targets of the IFN-alpha-induced cellular antiviral program in Huh7 cells expressing HCV subgenomic replicons. Our results revealed a tight linkage between translation, assembly of replication complexes and viral RNA synthesis, and indicated that the stability of amplified plus strand RNA was reduced in the presence of the cytokine. Moreover, HCV internal ribosomal entry site (IRES)-directed translation was inhibited approximately 2-fold in IFN-treated cells. In contrast, the synthesis of viral RNA did not seem to be directly affected by the antiviral program induced by the cytokine. Our results were consistent with a model predicting that the IFN-alpha-induced antiviral program could inhibit multiple steps of the HCV replication cycle, leading to a reduction in viral protein synthesis and eventually inhibition of viral RNA amplification.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231387     DOI: 10.1016/j.virol.2004.04.031

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC.

Authors:  Sung-Jae Park; Young S Hahn
Journal:  Rev Infect       Date:  2010-07-01

2.  Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line.

Authors:  L Yao; H Dong; H Zhu; D Nelson; C Liu; L Lambiase; X Li
Journal:  J Viral Hepat       Date:  2011-03-16       Impact factor: 3.728

3.  Knockdown of USP18 increases α 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells.

Authors:  E J Murray; Frances Burden; Nigel Horscroft; Caroline Smith-Burchnell; Mike Westby
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

4.  Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.

Authors:  Vanessa Escuret; Amaury Martin; David Durantel; Romain Parent; Olivier Hantz; Christian Trépo; Thierry Menguy; Emmanuel Bottius; Jerome Dardy; Jean Maral; Jean Louis Escary; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2006-10-09       Impact factor: 5.191

Review 5.  Hepatitis C virus infection--pathobiology and implications for new therapeutic options.

Authors:  Gary L Davis; Kris Krawczynski; Gyongyi Szabo
Journal:  Dig Dis Sci       Date:  2007-02-27       Impact factor: 3.199

Review 6.  Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response.

Authors:  Kate S O'Connor; Jacob George; David Booth; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 7.  Interaction of hepatitis C virus with the type I interferon system.

Authors:  Friedemann Weber
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 8.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

9.  Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus.

Authors:  Dong Jiang; Haitao Guo; Chunxiao Xu; Jinhong Chang; Baohua Gu; Lijuan Wang; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

Review 10.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.

Authors:  Barbara Rehermann
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.